Prospective study of troponin I as a predictor of cardiotoxicity induced by lapatinib combined with doxorubicin in patients with breast cancer

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200061912

Enrollment

Unknown

Registered

2022-07-11

Start date

2022-09-01

Completion date

Unknown

Last updated

2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

Group 1 :

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Breast cancer diagnosed by histopathology, the chemotherapy regimen is doxorubicin combined with lapatinib, and 21 days is a chemotherapy cycle; 2. The quality of life (KPS) score exceeds 60 points, and the expected survival time is longer than 6 months; 3. Those who have never received radiotherapy and/or chemotherapy before; 4. No history of heart disease or heart failure; 5. Patients who have never had acute myocardial infarction in the past six months.

Exclusion criteria

Exclusion criteria: 1. Patients who failed to complete the course of chemotherapy; 2. Patients who are unwilling to accept the trial.

Design outcomes

Primary

Measure	Time frame
Troponin I concentration ;Left Ventricular Ejection Fractions;	—

Countries

China

Contacts

Public ContactChenxu Ni

Shanghai Tenth People's Hospital

nichenxu@126.com+86 13524506143

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026